Entasis Therapeutics Holdings Inc. ETTX
We take great care to ensure that the data presented and summarized in this overview for Entasis Therapeutics Holdings Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in ETTX
Top Purchases
Top Sells
About ETTX
Insider Transactions at ETTX
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jul 11
2022
|
Innoviva, Inc. |
BUY
Open market or private purchase
|
Indirect |
7,598,814
+20.61%
|
$15,197,628
$2.2 P/Share
|
|
Jul 11
2022
|
Kristie Ann Wagner VP, Principal Fin & Acct Off |
SELL
Sale (or disposition) back to the issuer
|
Direct |
80,500
-100.0%
|
-
|
|
Jul 11
2022
|
Anna Diaz Triola Chief Commercial Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
125,000
-100.0%
|
-
|
|
Jul 11
2022
|
Ruben Tommasi Chief Scientific Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
150,000
-100.0%
|
-
|
|
Jul 11
2022
|
Matthew Ronsheim Chief of Pharma Sciences & MFG |
SELL
Sale (or disposition) back to the issuer
|
Direct |
150,000
-100.0%
|
-
|
|
Jul 11
2022
|
Manoussos Perros President and CEO |
SELL
Sale (or disposition) back to the issuer
|
Direct |
478,500
-100.0%
|
-
|
|
Jul 11
2022
|
John Patrick Mueller Chief Development Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
150,000
-100.0%
|
-
|
|
Jul 11
2022
|
David D. Meek Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
27,500
-100.0%
|
$55,000
$2.2 P/Share
|
|
Jul 11
2022
|
Howard Mayer Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
27,500
-100.0%
|
$55,000
$2.2 P/Share
|
|
Jul 11
2022
|
Elizabeth M Keiley General Counsel |
SELL
Sale (or disposition) back to the issuer
|
Direct |
150,000
-100.0%
|
-
|
|
Jul 11
2022
|
David C Hastings Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
27,500
-100.0%
|
$55,000
$2.2 P/Share
|
|
Jul 11
2022
|
Heather A. Berger Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
27,500
-100.0%
|
$55,000
$2.2 P/Share
|
|
Jul 11
2022
|
David Altarac Chief Medical Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
150,000
-100.0%
|
-
|
|
Jul 08
2022
|
Innoviva, Inc. |
BUY
Open market or private purchase
|
Indirect |
11,671,662
+35.0%
|
$23,343,324
$2.2 P/Share
|
|
Jul 07
2022
|
Ruben Tommasi Chief Scientific Officer |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
39,596
-100.0%
|
$79,192
$2.2 P/Share
|
|
Jul 07
2022
|
Matthew Ronsheim Chief of Pharma Sciences & MFG |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
17,572
-100.0%
|
$35,144
$2.2 P/Share
|
|
Jul 07
2022
|
Manoussos Perros President and CEO |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
56,072
-100.0%
|
$112,144
$2.2 P/Share
|
|
Jul 07
2022
|
John Patrick Mueller Chief Development Officer |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
17,092
-100.0%
|
$34,184
$2.2 P/Share
|
|
Jul 07
2022
|
David D. Meek Director |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
22,000
-100.0%
|
$44,000
$2.2 P/Share
|
|
Jul 07
2022
|
Howard Mayer Director |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
22,000
-100.0%
|
$44,000
$2.2 P/Share
|
Last 12 Months Summary
Buy / Acquisition
0
Shares
From
0
Insiders
Sell / Disposition
0
Shares
From
0
Insiders